Login to Your Account

Interim Data Presented at AACR

Activartis in Partnering Talks Armed with Phase II Survival

By Nuala Moran
Staff Writer

Wednesday, April 10, 2013
Cancer specialist Activartis Biotech GmbH will present positive survival data from the Phase II trial of its dendritic cell therapy in treating glioblastoma at the American Association of Cancer Research (AACR) Wednesday, as it steps up efforts to find a partner to back a Phase III study.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription